专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2007253715B2 C-glycolipids with enhanced TH-1 profile 未知
公开(公告)号：AU2007253715B2
公开(公告)日：2013-03-14
申请号：AU2007253715
申请日：2007-05-22
申请人： UNIV NEW YORK , UNIV CITY NEW YORK RES FOUND , THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK INC
发明人： YANG GUANGLI , CHEN GUANGWU , FRANCK RICHARD , TSUJI MORIYA
IPC分类号： C07D309/10 , A61K31/70 , A61K31/7008 , C07H7/02
摘要： The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI -type immune response characterized by enhanced IL- 12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.

2. 发明申请

WO2003050308A1 HIGHLY-SENSITIVE GENOMIC ASSAYS EMPLOYING CHIMERIC BACTERIOPHAGE STANDARDS 审中-公开
标题翻译：采用CHIMERIC BACTERIOPHAGE标准的高敏感基因测定
公开(公告)号：WO2003050308A1
公开(公告)日：2003-06-19
申请号：PCT/US2002/038612
申请日：2002-12-04
申请人： THE AARON DIAMOND AIDS RESEARCH CENTER , ZHANG, Linqi , HO, David, D.
发明人： ZHANG, Linqi , HO, David, D.
IPC分类号： C12Q1/68
CPC分类号： C12N7/00 , C12N2730/10122 , C12N2795/14111 , C12N2795/14143 , C12Q1/706 , C12Q2561/113 , C12Q2545/114 , C12Q2545/101
摘要： Methods are provided for sensitively quantitating at least one pre-selected DNA sequence in a biological sample utilizing hybridization methodology, the method employing as an internal standard an infectious bacteriophage particle comprising a detectable target DNA sequence other than that present in the pre-selected DNA sequence or in DNA quantitated from the biological sample, and as an external standard, an infectious bacteriophage particle comprising at least the pre-selected DNA sequence.
摘要翻译：提供了使用杂交方法灵敏定量生物样品中至少一个预先选择的DNA序列的方法，该方法使用包含可检测的靶DNA序列的感染性噬菌体颗粒作为内标，所述感染性噬菌体颗粒除了存在于预先选择的DNA序列之外或在生物样品中定量的DNA中，并且作为外部标准，是至少包含预先选择的DNA序列的感染性噬菌体颗粒。

3. 发明申请

WO2007137258A3 C-GLYCOLIPIDS WITH ENHANCED TH-1 PROFILE 审中-公开
公开(公告)号：WO2007137258A3
公开(公告)日：2007-11-29
申请号：PCT/US2007/069461
申请日：2007-05-22
申请人： NEW YORK UNIVERSITY , RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK , THE AARON DIAMOND AIDS RESEARCH CENTER FOR THE CITY OF NEW YORK, INC. , TSUJI, Moriya , CHEN, Guangwu , FRANCK, Richard , YANG, Guangli
发明人： TSUJI, Moriya , CHEN, Guangwu , FRANCK, Richard , YANG, Guangli
IPC分类号： A61K31/70 , C07H7/02
摘要： The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI -type immune response characterized by enhanced IL- 12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.

4. 发明申请

WO1998005798A1 HIV CORECEPTOR MUTANTS 审中-公开
标题翻译： HIV CORECEPTOR MUTANT
公开(公告)号：WO1998005798A1
公开(公告)日：1998-02-12
申请号：PCT/US1997013946
申请日：1997-08-07
申请人： THE AARON DIAMOND AIDS RESEARCH CENTER
发明人： THE AARON DIAMOND AIDS RESEARCH CENTER , LANDAU, Nathaniel, R. , KOUP, Richard, A. , LIU, Rong , PAXTON, William
IPC分类号： C12Q01/70
CPC分类号： C07K14/7158 , A01K2217/05 , C12Q1/703 , C12Q2600/156
摘要： Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the beta -chemokines RANTES, MIP-1 alpha , and MIP-1 beta . It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistent to HIV infection; in vitro infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.
摘要翻译： HIV-1进入靶细胞需要细胞表面CD4以及额外的宿主细胞辅因子。最近鉴定了一种在转化的T细胞系中适应生长的病毒感染所需的辅因子，并命名为fusin。然而，Fusin不促进被认为是体内关键致病菌株的巨噬细胞 - 嗜性病毒的进入。现在已经确定，由HIV-1的初级巨噬细胞 - 嗜热菌株的包膜糖蛋白介导的进入的主要辅助因子是CC-CKR5，β-chemokines RANTES，MIP-1α和MIP-1β的受体。还发现对CKR-5受体的突变是纯合的个体对HIV感染是抗性的; 体外感染需要比正常细胞高1000倍的HIV。突变导致CKR-5表达的完全抑制。

5. 发明申请

WO2004035006A2 METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST HIV 审中-公开
标题翻译：艾滋病免疫方法和组合物
公开(公告)号：WO2004035006A2
公开(公告)日：2004-04-29
申请号：PCT/US2003/033112
申请日：2003-10-17
申请人： THE AARON DIAMOND AIDS RESEARCH CENTER , HUANG, Yaoxing , HO, David, D. , CHEN, Zhiwei
发明人： HUANG, Yaoxing , HO, David, D. , CHEN, Zhiwei
IPC分类号： A61K
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/24043 , C12N2710/24143 , C12N2740/16043 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322
摘要： The present invention relates to nucleic acid and attenuated vaccinia vectors for prophylactic use against HIV infection, as well as methods of eliciting immune responses in subjects susceptible to HIV infection. The prophylactic vaccine regimen of the invention involves immunological priming with an inoculum comprising two novel DNA vectors, followed by boosting with a Modified Vaccinia Ankara (MVA) recombinant viral vector expressing the corresponding HIV proteins.
摘要翻译：本发明涉及用于预防HIV感染的核酸和减毒痘苗载体，以及在易感HIV感染的受试者中引发免疫应答的方法。本发明的预防性疫苗方案涉及用包含两种新型DNA载体的接种物的免疫启动，随后用表达相应的HIV蛋白质的改良的痘苗安卡拉（MVA）重组病毒载体进行加强。

6. 发明公开

EP1570067A2 METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST HIV 审中-公开
标题翻译：方法和组合物免疫对HIV
公开(公告)号：EP1570067A2
公开(公告)日：2005-09-07
申请号：EP03777686.1
申请日：2003-10-17
申请人： The Aaron Diamond Aids Research Center
发明人： HUANG, Yaoxing , HO, David, D. , CHEN, Zhiwei
IPC分类号： C12P21/06 , C12N5/00 , C12N15/00 , C12N15/63 , A01N43/04
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/24043 , C12N2710/24143 , C12N2740/16043 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322
摘要： The present invention relates to nucleic acid and attenuated vaccinia vectors for prophylactic use against HIV infection, as well as methods of eliciting immune responses in subjects susceptible to HIV infection. The prophylactic vaccine regimen of the invention involves immunological priming with an inoculum comprising two novel DNA vectors, followed by boosting with a Modified Vaccinia Ankara (MVA) recombinant viral vector expressing the corresponding HIV proteins.

7. 发明公开

EP1296712A2 HIV-1 VACCINES AND SCREENING METHODS THEREFOR 审中-公开
标题翻译： HIV-1疫苗和筛选一种适合
公开(公告)号：EP1296712A2
公开(公告)日：2003-04-02
申请号：EP01948773.5
申请日：2001-06-27
申请人： The Aaron Diamond Aids Research Center
发明人： STAMATATOS, Leonidas , BARNETT, Susan , SHRIVASTAVA, Inresh
IPC分类号： A61K39/21
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K2039/525 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55566 , A61K2039/57 , C12N2740/16122 , C12N2740/16134
摘要： Methods for immunizing, and immunogen pharmaceutical compositions for eliciting a heterologous immune response to HIV-1 in an animal, preferably a human, are provided, utilizing a modified HIV-1 envelope protein or fragment or DNA encoding a modified HIV-1 envelope protein or fragment, the modified protein having a HIV-1 envelope protein V2 region deletion. A humoral response against heterologous HIV-1 strains is achieved.

8. 发明公开

EP1198468A1 STABILIZED VIRAL ENVELOPE PROTEINS AND USES THEREOF 审中-公开
标题翻译：稳定病毒包膜蛋白及其用途
公开(公告)号：EP1198468A1
公开(公告)日：2002-04-24
申请号：EP00944801.0
申请日：2000-06-23
申请人： PROGENICS PHARMACEUTICALS, INC. , The Aaron Diamond Aids Research Center
发明人： BINLEY, James, M. , SCHUELKE, Norbert , OLSON, William, C. , MADDON, Paul, J. , MOORE, John, P.
IPC分类号： C07H21/04 , C07K16/00 , C07K14/00 , A01N37/18 , A01N1/00 , A61K38/16 , C12Q1/68 , G01N33/53 , C12P21/06 , C12N15/00
CPC分类号： C07K16/1063 , A61K39/00 , A61K2039/53
摘要： This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provide a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.

9. 发明申请

US20100233207A1 C-GLYCOLIPIDS WITH ENHANCED TH-1 PROFILE 有权
标题翻译：具有增强TH-1型材的C-GLYCOLIPIDS
公开(公告)号：US20100233207A1
公开(公告)日：2010-09-16
申请号：US12302011
申请日：2007-05-22
申请人： Moriya Tsuji , Guangwu Chen , Richard W. Franck , Guangli Yang
发明人： Moriya Tsuji , Guangwu Chen , Richard W. Franck , Guangli Yang
IPC分类号： A61K39/39 , C07H7/02 , A61K39/00 , A61K39/12 , A61K39/21 , A61K39/015 , A61P35/00 , A61P37/08 , A61P33/06 , A61P11/06 , A61P31/18
CPC分类号： C07H13/06 , A61K31/7004 , A61K31/7028 , A61K31/7042 , C07H7/00 , C07H15/06
摘要： The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.
摘要翻译：本发明涉及新型合成的C-糖脂，其选择性诱导特征在于增强的IL-12分泌和增加树突状细胞活化的Th1型免疫应答。因此，本发明的化合物可直接用作治疗感染，癌症，细胞增殖性疾病和自身免疫性疾病。

10. 发明授权

US6057102A HIV coreceptor mutants 失效
标题翻译： HIV共同受体突变体
公开(公告)号：US6057102A
公开(公告)日：2000-05-02
申请号：US907468
申请日：1997-08-08
申请人： Nathaniel R. Landau , Richard A. Koup , Rong Liu , William Paxton
发明人： Nathaniel R. Landau , Richard A. Koup , Rong Liu , William Paxton
IPC分类号： C07K14/715 , C12Q1/70 , C12Q1/68
CPC分类号： C12Q1/703 , C07K14/7158 , A01K2217/05 , C12Q2600/156
摘要： Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta.. It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistent to HIV infection; in vitro infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.
摘要翻译： HIV-1进入靶细胞需要细胞表面CD4以及额外的宿主细胞辅因子。最近鉴定了一种在转化的T细胞系中适应生长的病毒感染所需的辅因子，并命名为fusin。然而，Fusin不促进被认为是体内关键致病菌株的巨噬细胞 - 嗜性病毒的进入。现在已经确定，由HIV-1的初级巨噬细胞 - 热带菌株的包膜糖蛋白引入的主要辅助因子是CC-CKR5，β-chemokines RANTES，MIP-1α和MIP-1β的受体。还发现对CKR-5受体的突变是纯合的个体对HIV感染是抗性的; 体外感染需要比正常细胞高1000倍的HIV。突变导致CKR-5表达的完全抑制。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式